Please wait while we load the requested 10-K report or click the link below:
Altimmune Announces Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update
Enrollment in the Phase 1 AdCOVID™ Clinical Trial has Commenced
Development of AdCOVID Vectors Targeting Emerging Variants
of the SARS-CoV-2 Virus has Begun
ALT-801 is Progressing Through the Phase 1 Clinical Trial
Solidly Capitalized to Advance Pipeline Candidates with $216 Million in
Cash and Short-Term Investments at Year-End
GAITHERSBURG, MD, February 25, 2021-- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December 31, 2020 and provided a corporate update.
“The past year has been a transformative time for our Company as we made substantial progress in each of our five portfolio programs,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer. “During the year we initiated multiple clinical trials for several of our product candidates (T-COVID™, ALT-801 and HepTcell™) and completed preparations to begin a Phase 1 clinical trial of AdCOVID, which has begun enrolling volunteers. These achievements have set the stage for a busy and exciting year ahead, as we anticipate multiple data readouts from these programs over the coming months. With two promising technology platforms and five novel product candidates now advancing in clinical development, we believe 2021 has the potential to be a momentous year for Altimmune.”
Commenced enrollment in AdCOVID Phase 1 clinical trial evaluating a novel, needle-free intranasal delivery approach for COVID-19 vaccination
Altimmune has commenced enrollment in its Phase 1 clinical trial of AdCOVID, which is designed to evaluate a needle-free intranasal delivery approach for vaccination against COVID-19. Altimmune believes AdCOVID has the potential to become a leading candidate for COVID-19 vaccination based on its ease of administration, and the potential for reduced disease transmission, and cold chain-free vaccine distribution, if the product is demonstrated to have extended stability at room temperature. As demonstrated in the NasoShield and NasoVax clinical trials, the Company believes the expected attributes of AdCOVID make it ideally suited for use in a pediatric setting as the intranasal administration and expected tolerability profile are well suited to meet the needs of children.
The following information was filed by Altimmune, Inc. (ALT) on Thursday, February 25, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Altimmune, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Altimmune, Inc..